공유는 배려입니다!


Excerpt

The American Medical Association (AMA) Current Procedural Terminology (CPT ® ) Panel has established a unique CPT code for the first 3-antigen (S, Pre-S1, Pre-S2) Hepatitis B (HBV) vaccine, developed by VBI Vaccines. This will differentiate this vaccine from other approved, single-antigen HBV vaccines. The 3-antigen HBV vaccine is approved and commercially available in Israel, and is currently awaiting marketing approval in the U.S. and Europe.

Article Summary

A unique Current Procedural Terminology (CPT ® ) code has been issued by the American Medical Association (AMA) for VBI Vaccines’ 3-antigen (S, Pre-S1, Pre-S2) Hepatitis B (HBV) vaccine, currently under review for marketing approval in the U.S. and Europe. The vaccine will, once approved, be differentiated from other single-antigen HBV vaccines
through this code. “The AMA’s issuance of a unique CPT code for a 3-antigen HBV vaccine enables a streamlined reimbursement process for our vaccine candidate that is distinct from the process for the other approved, single-antigen HBV vaccines,” said Jeff Baxter, President, and CEO.

About CPT ® Codes
CPT codes provide a universal language to denote medical services and procedures and are the most widely accepted medical nomenclature across the U.S. to report medical, surgical, and diagnostic services and procedures to public and private health insurance programs for reimbursement purposes. CPT codes are developed and maintained by the AMA, of which CPT ® is a trademark.

About Hepatitis B
With over 290 million people infected globally, HBV is one of the world’s most significant infectious disease threats and the leading cause of liver disease, which is difficult to cure. Complications from HBV cause an estimated 900,000 people to die each year.

About VBI’s 3-antigen Hepatitis B vaccine
The only 3-antigen hepatitis B vaccine is approved and commercially available in Israel under the name Sci-B-Vac. Data from VBI’s Phase 3 clinical program, consisting of two studies, provided the basis for the regulatory submissions in the U.S., Europe, and Canada.

To learn more, visit https://www.vbivaccines.com/sci-b-vac/.

About VBI Vaccines
The biopharmaceutical company develops vaccine candidates designed to draw on the natural power of the human immune system, through an innovative approach to virus-like particles (“VLPs”) including a proprietary enveloped VLP (“eVLP”) platform technology. VBI addresses significant infectious diseases as well as aggressive cancers.

(Source: VBI Vaccines, 1 st July 2021)